Insider Selling: Aura Biosciences (NASDAQ:AURA) Insider Sells 16,928 Shares of Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Los Pinos Elisabet De sold 16,928 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $4.86, for a total value of $82,270.08. Following the completion of the sale, the insider directly owned 457,463 shares of the company’s stock, valued at approximately $2,223,270.18. The trade was a 3.57% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Los Pinos Elisabet De also recently made the following trade(s):

• On Wednesday, October 29th, Los Pinos Elisabet De sold 9,049 shares of Aura Biosciences stock. The shares were sold at an average price of $6.35, for a total value of $57,461.15.

Aura Biosciences Stock Performance

AURA traded down $0.05 during trading on Tuesday, hitting $4.97. The stock had a trading volume of 217,669 shares, compared to its average volume of 164,885. Aura Biosciences, Inc. has a 12 month low of $4.34 and a 12 month high of $8.27. The company has a 50 day simple moving average of $5.74 and a 200-day simple moving average of $6.13.

Aura Biosciences (NASDAQ:AURA) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.06. As a group, analysts expect that Aura Biosciences, Inc. will post -1.66 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on AURA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aura Biosciences in a research report on Monday, December 29th. Evercore ISI began coverage on shares of Aura Biosciences in a research note on Tuesday, November 25th. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $20.50.

Hedge Funds Weigh In On Aura Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in AURA. Tower Research Capital LLC TRC increased its position in shares of Aura Biosciences by 49.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock valued at $40,000 after buying an additional 2,104 shares in the last quarter. Water Island Capital LLC acquired a new position in Aura Biosciences during the third quarter worth approximately $64,000. 49 Wealth Management LLC bought a new stake in Aura Biosciences in the 3rd quarter valued at $66,000. Invesco Ltd. acquired a new stake in shares of Aura Biosciences during the 2nd quarter worth about $76,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Aura Biosciences by 24.3% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 12,453 shares of the company’s stock worth $78,000 after buying an additional 2,434 shares during the period. Institutional investors and hedge funds own 96.75% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences is a clinical?stage biopharmaceutical company focused on the development of novel virus?like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non?ophthalmic settings, leveraging precision activation via near?infrared light to induce localized tumor cell apoptosis and stimulate anti?tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.